Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. News
  7. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : announces sales growth over the first 9 months of 2020

10/22/2020 | 01:25am EDT

Around the world, COVID-19 cases are on the rise again. Despite the challenges presented by the pandemic, our teams' commitment to delivering for patients remains as strong as ever. That's why we are especially pleased to announce our positive Q3 financial results. These results reflect both our commitment to patients and the resiliency of our portfolio. Our Q3 sales grew by 2.2% at constant exchange rates over the first nine months of 2020, despite the continuing negative impact of the COVID-19 pandemic. These results were driven by sales growth of 5.1% within our resilient Specialty Care portfolio.

We are also pleased to confirm our 2020 full-year guidance, with Group sales growth greater than +2.0% at constant currency and Core Operating margin greater than 30.0% of net sales.

Our late-stage R&D pipeline has also progressed for Cabometyx®, Somatuline® and palovarotene. We are further optimistic about growing our pipeline thanks to the recent appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, who is charged with business development and alliance management.

'The Group delivered a resilient performance in the third quarter, despite the continued impact of the pandemic, and I am pleased to confirm our 2020 full-year financial objectives,' said David Loew, CEO. 'Our pipeline achieved notable progress with incremental positive data on Cabometyx and palovarotene, supporting our intention to bring these important therapies to patients. I look forward to sharing my long-term vision for Ipsen and the outcomes of a comprehensive strategic review at our Capital Markets Day on December 1st.'

For more information, see the press release here.

Disclaimer

Ipsen SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:24:06 UTC


© Publicnow 2020
All news about IPSEN
06/18IPSEN  : A year-long partnership with the ISPC
PU
06/17IPSEN  : launches Perspectives Matter around World Kidney Cance...
PU
06/14ISPRM 2021 : New Ipsen analysis highlights potential treatment gap in adults liv..
AQ
06/11IPSEN  : Finds Potential Treatment Gap Among Spasticity Patients in US
MT
06/11IPSEN  : ISPMR 2021 – 11 June 2021.pdf
PU
06/07IPSEN  : Exelixis Say Phase 3 Trial of Cabozantinib Drug in Differentiated Thyro..
MT
06/07IPSEN  : Exelixis COSMIC-311 ASCO – 7 June 2021.pdf
PU
06/05IPSEN  : World Environment Day 2021
PU
05/31TODAY'S ANALYST RECOMMENDATIONS : Advanced Micro Devices, AstraZeneca, Bodycote,..
05/31IPSEN  : US FDA Accepts Ipsen's Approval Request For Ultra-Rare Genetic Disorder..
MT
More news
Financials
Sales 2021 2 737 M 3 253 M 3 253 M
Net income 2021 542 M 644 M 644 M
Net Debt 2021 83,7 M 99,5 M 99,5 M
P/E ratio 2021 13,7x
Yield 2021 1,15%
Capitalization 7 378 M 8 747 M 8 769 M
EV / Sales 2021 2,73x
EV / Sales 2022 2,59x
Nbr of Employees 5 703
Free-Float 41,9%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 91,03 €
Last Close Price 89,20 €
Spread / Highest target 26,7%
Spread / Average Target 2,05%
Spread / Lowest Target -15,9%
EPS Revisions
Managers and Directors
NameTitle
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN31.37%8 747
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795